Amylyx Pharmaceuticals Faces Investigation Over Potential Breaches of Fiduciary Duties

Thursday, Nov 13, 2025 2:41 pm ET1min read

Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of Amylyx Pharmaceuticals (NASDAQ: AMLX). Investors who currently own shares of Amylyx Pharmaceuticals stock are encouraged to visit the firm's website or contact Phillip Kim for more information. The Rosen Law Firm has a track record of success in securities class actions and shareholder derivative litigation.

Amylyx Pharmaceuticals Faces Investigation Over Potential Breaches of Fiduciary Duties

Comments



Add a public comment...
No comments

No comments yet